Spleen News and Research

RSS
JAK oral medication produces lasting relief for patients with myelofibrosis: Researchers

JAK oral medication produces lasting relief for patients with myelofibrosis: Researchers

Incyte Corporation enters SPA agreement with FDA for INCB18424 inhibitor

Incyte Corporation enters SPA agreement with FDA for INCB18424 inhibitor

Johns Hopkins Children's Center urges new screening program to improve sickle cell trait

Johns Hopkins Children's Center urges new screening program to improve sickle cell trait

David Mosser to discuss primary duty of macrophages at American Physiological Society conference

David Mosser to discuss primary duty of macrophages at American Physiological Society conference

FDA grants LFB's recombinant anti-CD20 monoclonal antibody orphan drug status for CLL

FDA grants LFB's recombinant anti-CD20 monoclonal antibody orphan drug status for CLL

Genzyme announces publication of phase 2 clinical trial results of eliglustat tartrate for Gaucher disease

Genzyme announces publication of phase 2 clinical trial results of eliglustat tartrate for Gaucher disease

New T cell engineering approach can improve success rate of immune-cell therapies

New T cell engineering approach can improve success rate of immune-cell therapies

NKTreg white blood cells migrate into liver, suppress immune responses: Research

NKTreg white blood cells migrate into liver, suppress immune responses: Research

Study results provide rationale for use of PI3K inhibitors in therapeutic settings

Study results provide rationale for use of PI3K inhibitors in therapeutic settings

FDA grants Orphan Drug Designation to YM BioSciences' JAK1/2 inhibitor

FDA grants Orphan Drug Designation to YM BioSciences' JAK1/2 inhibitor

Vesicular stomatitis virus kills tumour, stimulates immune response against cancer: Research

Vesicular stomatitis virus kills tumour, stimulates immune response against cancer: Research

YM concludes dose-escalation in CYT387 Phase I/II clinical trial for myelofibrosis

YM concludes dose-escalation in CYT387 Phase I/II clinical trial for myelofibrosis

Life Technologies, UCSD Moores Cancer Center to use SOLiD 4 technology to study CLL

Life Technologies, UCSD Moores Cancer Center to use SOLiD 4 technology to study CLL

New drug to treat chronic pain in SCD patients

New drug to treat chronic pain in SCD patients

Research findings may help identify human TOR kinase inhibitors

Research findings may help identify human TOR kinase inhibitors

Study links high-fat diet as potential cause of prostatic diseases

Study links high-fat diet as potential cause of prostatic diseases

Shire presents positive data from TKT-025 EXT Phase I/II study for VPRIV in type 1 Gaucher disease patients

Shire presents positive data from TKT-025 EXT Phase I/II study for VPRIV in type 1 Gaucher disease patients

Eisai reports preliminary results from Dacogen for Injection Phase III study in AML

Eisai reports preliminary results from Dacogen for Injection Phase III study in AML

Avila's AVL-292 demonstrates disease-modifying effects in prophylactic, therapeutic models of rheumatoid arthritis

Avila's AVL-292 demonstrates disease-modifying effects in prophylactic, therapeutic models of rheumatoid arthritis

Gilead Sciences signs definitive agreement to acquire CGI Pharmaceuticals

Gilead Sciences signs definitive agreement to acquire CGI Pharmaceuticals

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.